积极优化慢性阻塞性肺疾病管理降低心肺事件风险

doi:10.19983/j.issn.2096-8493.20230103

摘要/Abstract

中图分类号:

R563
R54

陈海杰, 陈亚红. 积极优化慢性阻塞性肺疾病管理降低心肺事件风险[J]. 结核与肺部疾病杂志, 2023, 4(5): 337-341. doi: 10.19983/j.issn.2096-8493.20230103

Chen Haijie, Chen Yahong. Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event[J]. Journal of Tuberculosis and Lung Disease, 2023, 4(5): 337-341. doi: 10.19983/j.issn.2096-8493.20230103

参考文献 48

[1]	Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med, 2018, 6(6):421-430. doi:10.1016/S2213-2600(18)30103-6. pmid: 29650407
[2]	Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis, 2018, 27(13):1353-1364. doi:10.2147/COPD.S161555.
[3]	Mannino DM, Higuchi K, Yu TC, et al. Economic Burden of COPD in the Presence of Comorbidities. Chest, 2015, 148(1):138-150. doi:10.1378/chest.14-2434. pmid: 25675282
[4]	André S, Conde B, Fragoso E, et al. COPD and Cardiovascular Disease. Pulmonology, 2019, 25(3):168-176. doi:10.1016/j.pulmoe.2018.09.006. pmid: 30527374
[5]	Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med, 2015, 3(8):631-639. doi:10.1016/S2213-2600(15)00241-6. pmid: 26208998
[6]	Ställberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med, 2018, 28(1):33. doi:10.1038/s41533-018-0101-y.
[7]	Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest, 2005, 128(4):2640-2646. doi:10.1378/chest.128.4.2640. pmid: 16236937
[8]	Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med, 2011, 105(10):1516-1522. doi:10.1016/j.rmed.2011.04.005. pmid: 21684731
[9]	Natali D, Cloatre G, Hovette P, et al. Screening for comorbidities in COPD. Breathe (Sheff), 2020, 16(1):190315. doi:10.1183/20734735.0315-2019.
[10]	Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis, 2018, 12:1753465817750524. doi:10.1177/1753465817750524.
[11]	Brassington K, Selemidis S, Bozinovski S, et al. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin Sci (Lond), 2019, 133(7):885-904. doi:10.1042/CS20180316. pmid: 30979844
[12]	Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7):574-580. doi:10.1136/thx.2003.019588. pmid: 15223864
[13]	Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J, 2009, 33(5):1165-1185. doi:10.1183/09031936.00128008. pmid: 19407051
[14]	Calverley PM, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD, 2006, 3(4):233-242. doi:10.1080/15412550600977544. pmid: 17361504
[15]	Tousoulis D, Papageorgiou N, Androulakis E, et al. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev, 2011, 25(6):239-245. doi:10.1016/j.blre.2011.05.001. pmid: 21652129
[16]	Langer D, Ciavaglia CE, Neder JA, et al. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med, 2014, 8(6):731-749. doi:10.1586/17476348.2014.949676.
[17]	Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med, 2010, 362(3):217-227. doi:10.1056/NEJMoa0808836.
[18]	Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005, 171(6):591-597. doi:10.1164/rccm.200407-867OC.
[19]	Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res, 1989, 64(5):827-852. doi:10.1161/01.res.64.5.827. pmid: 2523260
[20]	Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med, 2015, 109(7):785-802. doi:10.1016/j.rmed.2015.03.010. pmid: 25892293
[21]	Ball MK, Waypa GB, Mungai PT, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med, 2014, 189(3):314-324. doi:10.1164/rccm.201302-0302OC.
[22]	Tuder RM, Yun JH, Bhunia A, et al. Hypoxia and chronic lung disease. J Mol Med (Berl), 2007, 85(12):1317-1324. doi:10.1007/s00109-007-0280-4.
[23]	Goudis CA, Konstantinidis AK, Ntalas IV, et al. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol, 2015, 199:264-273. doi:10.1016/j.ijcard.2015.06.096. pmid: 26218181
[24]	Laratta CR, van Eeden S. Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int, 2014, 2014:528789. doi:10.1155/2014/528789.
[25]	Bhatt SP. Cardiac Considerations in Chronic Lung Disease. Berlin: Springer, 2020. doi:10.1007/978-3-030-43435-9.
[26]	Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J, 2023, 61(4):2300239. doi:10.1183/13993003.00239-2023.
[27]	Cazzola M, Calzetta L, Matera MG, et al. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med, 2015, 109(8):1019-1025. doi:10.1016/j.rmed.2015.05.021. pmid: 26111914
[28]	Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006, 113(19):2335-2362. doi:10.1161/CIRCULATIONAHA.104.482570. pmid: 16702488
[29]	孙永昌. 一呼一吸总关心. 中华结核和呼吸杂志, 2019, 42(11):804-805. doi:10.3760/cma.j.issn.1001-0939.2019.11.002.
[30]	Horita N, Nagashima A, Kaneko T. Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. JAMA, 2017, 318(13):1274-1275. doi:10.1001/jama.2017.11903. pmid: 28973232
[31]	Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med, 2018, 6(5):368-378. doi:10.1016/S2213-2600(18)30054-7. pmid: 29477448
[32]	Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J, 2018, 52(6):1801586. doi:10.1183/13993003.01586-2018.
[33]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组,《慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识》撰写组. 慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识. 中华结核和呼吸杂志, 2022, 45(12):1180-1191. doi:10.3760/cma.j.cn112147-20220505-00380.
[34]	Jing X, Li Y, Xu J. Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Can Respir J, 2018, 2018:7097540. doi:10.1155/2018/7097540.
[35]	Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 2018, 378(18):1671-1680. doi:10.1056/NEJMoa1713901.
[36]	Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med, 2020, 383(1):35-48. doi:10.1056/NEJMoa1916046.
[37]	Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax, 2017, 72(3):271-276. doi:10.1136/thoraxjnl-2016-208412. pmid: 27927840
[38]	Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, 2005(4): CD003566. doi:10.1002/14651858.CD003566.
[39]	Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med, 2012, 12:48. doi:10.1186/1471-2466-12-48. pmid: 22947076
[40]	Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med, 2010, 170(10):880-887. doi:10.1001/archinternmed.2010.112. pmid: 20498416
[41]	Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart, 2016, 2(23):1909-1914. doi:10.1136/heartjnl-2016-309458.
[42]	Wu J, Sin DD. Improved patient outcome with smoking cessation: when is it too late? Int J Chron Obstruct Pulmon Dis, 2011, 6:259-267. doi:10.2147/COPD.S10771.
[43]	Zhang J, Ou JX, Bai CX. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology, 2011, 16(8):1165-1172. doi:10.1111/j.1440-1843.2011.02062.x. pmid: 21910781
[44]	McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, 2015(2): CD003793. doi:10.1002/14651858.
[45]	Spruit MA, Burtin C, De Boever P, et al. COPD and exercise: does it make a difference? Breathe (Sheff), 2016, 12(2):38-49. doi:10.1183/20734735.003916.
[46]	Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med, 2011, 11(20):1-7. doi:10.1186/1471-2466-11-20.
[47]	Huang CL, Nguyen PA, Kuo PL, et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed, 2013, 111(2):507-511. doi:10.1016/j.cmpb.2013.05.006.
[48]	Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis, 2020, 99(1):204-213. doi:10.1016/j.ijid.2020.07.038.

积极优化慢性阻塞性肺疾病管理降低心肺事件风险

Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	曾文美, 吴苏龙, 刘灼帆, 袁茏, 陈碧琳, 荣艳. 便携式睡眠监测对阻塞性睡眠呼吸暂停低通气患者整夜病情评估及心血管疾病风险因素分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 1-7.
[2]	孟雯. 系统化运动护理方案在糖尿病合并慢性阻塞性肺疾病患者护理中的应用价值[J]. 结核与肺部疾病杂志, 2024, 5(S): 111-113.
[3]	刘丽君. 慢性淋巴细胞性甲状腺炎伴甲状腺功能减退症合并双肺炎的临床护理效果分析[J]. 结核与肺部疾病杂志, 2024, 5(S): 132-135.
[4]	杨红雨, 刘巧林, 康雄, 杨晓丽. 结核病与AIDS共病预后影响因素及综合防治策略研究进展[J]. 结核与肺部疾病杂志, 2024, 5(6): 590-596.
[5]	何繁漪, 陆霓虹, 杜映荣. 结核病与COVID-19相互作用的研究进展[J]. 结核与肺部疾病杂志, 2024, 5(4): 345-351.
[6]	朋毛措, 谢俊刚. 免疫细胞在慢性阻塞性肺疾病并发心血管疾病中的研究进展[J]. 结核与肺部疾病杂志, 2024, 5(2): 179-185.
[7]	倪楠, 陈晴, 唐先珍, 邹莉萍, 梁丽, 吴桂辉, 毛俐. 203例老年肺结核合并2型糖尿病患者耐药状况及影响因素分析[J]. 结核与肺部疾病杂志, 2024, 5(1): 28-36.
[8]	杨梁梓, 王玉香, 谭洁, 郑俊峰, 付亮, 邓国防, 张培泽. 合并糖尿病的药物敏感性肺结核患者治疗强化期痰菌延迟阴转的影响因素分析[J]. 结核与肺部疾病杂志, 2023, 4(5): 370-375.
[9]	罗晨阳, 何志义. 慢性阻塞性肺疾病与合并症[J]. 结核与肺部疾病杂志, 2023, 4(5): 407-412.
[10]	饶立歆, 沈鑫. 携手并进终结结核病终结艾滋病[J]. 结核与肺部疾病杂志, 2022, 3(6): 429-430.
[11]	杨蕊, 许琳, 李玲. 2010—2020年云南省MTB/HIV双重感染流行特征分析[J]. 结核与肺部疾病杂志, 2022, 3(6): 437-442.
[12]	罗丹, 陈松华, 张钰, 王伟, 吴倩, 吴勇浩, 刘魁, 陈彬. 2015—2021年浙江省MTB/HIV双重感染筛查现况及趋势分析[J]. 结核与肺部疾病杂志, 2022, 3(6): 443-448.
[13]	周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 338-342.
[14]	刘玉坤, 郭智. 慢性髓系白血病与结核病共病研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 325-327.
[15]	郦源, 郭茹茹, 吕良敬. 结缔组织病合并结核病的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 309-314.